首页|Ginsenoside Rb1 in cardiovascular and cerebrovascular diseases:A review of therapeutic potentials and molecular mechanisms

Ginsenoside Rb1 in cardiovascular and cerebrovascular diseases:A review of therapeutic potentials and molecular mechanisms

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Cardiovascular and cerebrovascular diseases(CCVDs),which are circulatory system diseases caused by heart defects and vascular diseases,are the major noncommunicable diseases affecting global public health.With the improvement of economic level and the change of human lifestyle,the prevalence of CCVDs continues to increase.Ginseng(Panax ginseng C.A.Mey.)was widely used in traditional diseases due to its supposed tonic properties.Ginsenoside Rb1(G-Rb1)is the most abundant active ingredient with multiple pharmacological effects extracted from ginseng,which has been shown to have potential bene-fits on the cardiovascular system through a variety of mechanisms,including anti-oxidation,anti-inflammatory,regulation of vasodilation,reduction of platelet adhesion,influence of calcium ion chan-nels,improvement of lipid distribution,involving in glucose metabolism and controlling blood sugar.This review reviewed the protective effects of G-Rb1 on CCVDs and its potential mechanisms,such as atherosclerosis(AS),hypertension,coronary heart disease(CHD),ischemic stroke(IS)and periocular microvascular retinopathy.Finally,we reviewed and reported the results of in vivo and in vitro experi-ments using G-Rb1 to improve CCVDs,highlighted its efficacy,safety,and limitations.

atherosclerosiscardiovascular and cerebrovascular diseasescoronary heart diseaseginsenoside Rb1hypertensionischemic strokeperiocular microvascular retinopathy

Yueqin Song、Chen Chen、Wei Li

展开 >

College of Chinese Medicinal Materials,Jilin Agricultural University,Changchun 130118,China

School of Biomedical Sciences,University of Queensland,Brisbane,QLD 4072,Australia

College of Life Sciences,Engineering Research Center of the Chinese Ministry of Education for Bioreactor and Pharmaceutical Development,Jilin Agricultural University,Changchun 130118,China

Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicinal Materials,Changchun 130118,China

展开 >

2024

10.1016/j.chmed.2024.09.006

中草药(英文版)
天津药物研究院 中国医学科学院药用植物研究所

中草药(英文版)

CSTPCD
影响因子：0.6
ISSN：1674-6384
年,卷(期)：2024.16(4)